Cargando…

Can expressed prostatic secretions affect prostate biopsy decision of urologist?

OBJECTIVES: To evaluate the frequency of NIH category IV prostatitis, and the use of expressed prostatic secretions tests in an effort to improve the reliability of prostate specific antigen as an indicator, to avoid unnecessary prostate biopsy. MATERIALS AND METHODS: 178 expressed prostatic secreti...

Descripción completa

Detalles Bibliográficos
Autores principales: Ergün, Osman, Çapar, Erdem, Göğer, Yunus Emre, Ergün, Ayşe Gül
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Urologia 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6541132/
https://www.ncbi.nlm.nih.gov/pubmed/30648827
http://dx.doi.org/10.1590/S1677-5538.IBJU.2018.0292
_version_ 1783422725219418112
author Ergün, Osman
Çapar, Erdem
Göğer, Yunus Emre
Ergün, Ayşe Gül
author_facet Ergün, Osman
Çapar, Erdem
Göğer, Yunus Emre
Ergün, Ayşe Gül
author_sort Ergün, Osman
collection PubMed
description OBJECTIVES: To evaluate the frequency of NIH category IV prostatitis, and the use of expressed prostatic secretions tests in an effort to improve the reliability of prostate specific antigen as an indicator, to avoid unnecessary prostate biopsy. MATERIALS AND METHODS: 178 expressed prostatic secretion positive patients with serum prostate specific antigen levels of ≥ 2.5 ng / mL were included in present prospective study. The diagnostic evaluation included detailed history and physical examination, digital rectal examination, urine analysis, urine culture, and expressed prostatic secretions tests. Transrectal ultrasonography was used both to measure prostate volume and conduct 12 core prostate biopsy. RESULTS: The prevalence of NIH category IV prostatitis was 36.9% (178 / 482) in our population of men. In our study patients (n: 178) prostate biopsy results were classified as; 66 prostatitis, 81 BPH, and 31 Pca. In asymptomatic prostatitis group, expressed prostatic secretion mean leucocyte ratio was higher compared to other two groups (p < 0.0001). The relation between number of expressed prostatic secretion leucocytes and prostatitis, benign prostate hyperplasia, and prostate cancer is analyzed. If 16 is taken as the cut of number for leucocyte presence, its sensitivity is 0.92 (AUC = 0.78 p = 0.01). CONCLUSIONS: The number of leucocytes in expressed prostatic secretion is higher in the chronic prostatitis group. If the leukocyte presence of 16 and above is taken as the cut off point, the sensitivity becomes 0.92 (AUC = 0.78). We firmly believe that our new cut off value may be used as to aid prostate specific antigen and derivates while giving biopsy decision.
format Online
Article
Text
id pubmed-6541132
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Sociedade Brasileira de Urologia
record_format MEDLINE/PubMed
spelling pubmed-65411322019-06-12 Can expressed prostatic secretions affect prostate biopsy decision of urologist? Ergün, Osman Çapar, Erdem Göğer, Yunus Emre Ergün, Ayşe Gül Int Braz J Urol Original Article OBJECTIVES: To evaluate the frequency of NIH category IV prostatitis, and the use of expressed prostatic secretions tests in an effort to improve the reliability of prostate specific antigen as an indicator, to avoid unnecessary prostate biopsy. MATERIALS AND METHODS: 178 expressed prostatic secretion positive patients with serum prostate specific antigen levels of ≥ 2.5 ng / mL were included in present prospective study. The diagnostic evaluation included detailed history and physical examination, digital rectal examination, urine analysis, urine culture, and expressed prostatic secretions tests. Transrectal ultrasonography was used both to measure prostate volume and conduct 12 core prostate biopsy. RESULTS: The prevalence of NIH category IV prostatitis was 36.9% (178 / 482) in our population of men. In our study patients (n: 178) prostate biopsy results were classified as; 66 prostatitis, 81 BPH, and 31 Pca. In asymptomatic prostatitis group, expressed prostatic secretion mean leucocyte ratio was higher compared to other two groups (p < 0.0001). The relation between number of expressed prostatic secretion leucocytes and prostatitis, benign prostate hyperplasia, and prostate cancer is analyzed. If 16 is taken as the cut of number for leucocyte presence, its sensitivity is 0.92 (AUC = 0.78 p = 0.01). CONCLUSIONS: The number of leucocytes in expressed prostatic secretion is higher in the chronic prostatitis group. If the leukocyte presence of 16 and above is taken as the cut off point, the sensitivity becomes 0.92 (AUC = 0.78). We firmly believe that our new cut off value may be used as to aid prostate specific antigen and derivates while giving biopsy decision. Sociedade Brasileira de Urologia 2019-04-01 /pmc/articles/PMC6541132/ /pubmed/30648827 http://dx.doi.org/10.1590/S1677-5538.IBJU.2018.0292 Text en https://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Ergün, Osman
Çapar, Erdem
Göğer, Yunus Emre
Ergün, Ayşe Gül
Can expressed prostatic secretions affect prostate biopsy decision of urologist?
title Can expressed prostatic secretions affect prostate biopsy decision of urologist?
title_full Can expressed prostatic secretions affect prostate biopsy decision of urologist?
title_fullStr Can expressed prostatic secretions affect prostate biopsy decision of urologist?
title_full_unstemmed Can expressed prostatic secretions affect prostate biopsy decision of urologist?
title_short Can expressed prostatic secretions affect prostate biopsy decision of urologist?
title_sort can expressed prostatic secretions affect prostate biopsy decision of urologist?
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6541132/
https://www.ncbi.nlm.nih.gov/pubmed/30648827
http://dx.doi.org/10.1590/S1677-5538.IBJU.2018.0292
work_keys_str_mv AT ergunosman canexpressedprostaticsecretionsaffectprostatebiopsydecisionofurologist
AT caparerdem canexpressedprostaticsecretionsaffectprostatebiopsydecisionofurologist
AT gogeryunusemre canexpressedprostaticsecretionsaffectprostatebiopsydecisionofurologist
AT ergunaysegul canexpressedprostaticsecretionsaffectprostatebiopsydecisionofurologist